170147-76-9

Basic information

• Product Name: N-BOC-5-HYDROXYINDOLINE
• Synonyms: N-BOC-5-HYDROXYINDOLINE;1H-Indole-1-carboxylicacid,2,3-dihydro-5-hydroxy-,1,1-diMethylethylester;tert-butyl 5-hydroxyindoline-1-carboxylate
• CAS NO: 170147-76-9
• Molecular Formula: C₁₃H₁₇NO₃
• Molecular Weight: 235.28
• Mol File: 170147-76-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-BOC-5-HYDROXYINDOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-BOC-5-HYDROXYINDOLINE(170147-76-9)
• EPA Substance Registry System: N-BOC-5-HYDROXYINDOLINE(170147-76-9)

Safety Data

• Hazardous Substances Data: 170147-76-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
N-BOC-5-HYDROXYINDOLINE is used as a building block in organic synthesis for its ability to form various biologically active compounds. The BOC group in its structure provides protection for the nitrogen atom, facilitating the synthesis of complex organic molecules.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, N-BOC-5-HYDROXYINDOLINE is used as a precursor for the development of novel drug molecules. The hydroxy group in its structure allows for further functionalization and modification, enabling the creation of pharmaceuticals with specific therapeutic properties.
Used in Pharmaceutical Industry:
N-BOC-5-HYDROXYINDOLINE is used as a key intermediate in the pharmaceutical industry for the synthesis of various drugs. Its unique structure and functional groups make it a valuable component in the development of new medications with improved efficacy and selectivity.
Used in Natural Product Synthesis:
N-BOC-5-HYDROXYINDOLINE is also utilized in the synthesis of natural products, where its BOC-protected structure allows for the selective formation of complex natural molecules with potential therapeutic applications.
Overall, N-BOC-5-HYDROXYINDOLINE's versatility in organic synthesis and medicinal chemistry, along with its potential applications in the pharmaceutical and natural product industries, highlights its importance as a valuable chemical intermediate.

Upstream product

• 226710-84-5 tert-butyl N-(3-phenylthio-3-butenyl)-N-(2-furyl)carbamate 
• 273408-46-1 tert-butyl 5-(benzyloxy)indoline-1-carboxylate 
• 170147-29-2 tert-butyl 5-(benzyloxy)-1H-indole-1-carboxylate 
• 1215-59-4 5-benzyloxy-1H-indole 
• 24424-99-5 di-tert-butyl dicarbonate 
• 92818-36-5 5-Benzyloxy-2,3-dihydro-1H-indole 
• 172078-33-0 2,3-Dihydro-1H-indol-5-ol 

Downstream Products

• 170148-06-8 5-(2-chloro-4-cyano-phenoxy)-2,3-dihydro-indole-1-carboxylic acid tert-butyl ester 
• 320783-99-1 4-(2,3-dihydro-1H-indol-5-yloxy)-benzonitrile 
• 320784-00-7 4-(2,3-dihydro-1H-indol-5-yloxy)-3-fluoro-benzonitrile 
• 170147-39-4 3-chloro-4-(indolin-5-yloxy)benzonitrile 
• 320784-35-8 3-bromo-4-(2,3-dihydro-1H-indol-5-yloxy)-benzonitrile 
• 1028304-85-9 4-[1-(4-phenoxy-benzyl)-2,3-dihydro-1H-indol-5-yloxy]-benzonitrile 
• 170148-16-0 3-chloro-4-[[1-(naphthalen-2-ylmethyl)indolin-5-yl]oxy]benzonitrile 
• 1026557-13-0 3-fluoro-4-[1-(4-phenoxy-benzyl)-2,3-dihydro-1H-indol-5-yloxy]-benzonitrile 
• 170148-19-3 3-chloro-4-[[1-(4-phenoxybenzyl)indolin-5-yl]oxy]benzonitrile 
• 1028271-76-2 3-bromo-4-[1-(4-phenoxy-benzyl)-2,3-dihydro-1H-indol-5-yloxy]-benzonitrile 
• 170148-21-7 4-[1-(4-benzyloxy-benzyl)-2,3-dihydro-1H-indol-5-yloxy]-3-chloro-benzonitrile 
• 170148-20-6 3-chloro-4-{1-[4-(4-isopropyl-phenoxy)-benzyl]-2,3-dihydro-1H-indol-5-yloxy}-benzonitrile 
• 273408-49-4 7-(2-formyl-4,5-dimethoxy-phenyl)-5-triisopropylsilanyloxy-2,3-dihydro-indole-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Indoline-1-formamide compound as well as preparation method and medical application thereof

The invention relates to a novel indoline-1-formamide compound for regulating or inhibiting the activity of a vascular endothelial growth factor receptor (VEGFR), a preparation method of the compoundand medical application of the compound. Specifically, t

BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS

Compounds that have agonist activity at one or more of the SlP receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at SlP receptors.

HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE

To provide a novel compound which has S1P receptor agonistic activity, exhibits excellent immunosuppressing effect, gives less adverse side effects, and can be orally administered. The invention provides a compound represented by general formula (I) (wherein A is a single bond, -O-, or - CH2-; R1 represents a hydrogen atom or a C1-C6 alkyl group, and V represents any one group selected from among the following groups (1) to (3) : (1) -G1-, (2) -G2-N(R2) -G3-, and (3) a group represented by formula 2, wherein each of Z1 and Z2 represents a hydrogen atom or a C1-C6 alkyl group, Z3 represents a hydrogen or the like, Q represents -CH2-O- or the like, and Y represents a group represented by foumula 3, a salt thereof, or a solvate thereof.

NPY ANTAGONISTS, PREPARATION AND USES

The present invention concerns novel compounds, their preparation and their uses, therapeutic uses in particular. More specifically it concerns derivative compounds having at least two aromatic cycles, their preparation and their uses, in particular in the area of human or animal health. These compounds have an affinity for the biological receptors of neuropeptide Y, NPY, present in the central and peripheral nervous systems. The compounds of the invention are preferably NPY antagonists, and more particularly antagonists of sub-type NPY Y1, and can therefore be used for the therapeutic or prophylactic treatment of any disorder involving NPY. The present invention also concerns pharmaceutical compositions containing said compounds, their preparation and their uses, as well as treatment methods using said compounds.

HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATON AND THERAPEUTIC USES

The present invention discloses novel compounds of Formula ( I ) or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention disclo

A novel class of inhibitors for human and rat steroid 5α-Reductases: Synthesis and biological evaluation of indoline and aniline derivatives. III

While searching for novel nonsteroidal inhibitors of human and rat prostatic 5α-reductases, we found a new series of indoline and aniline derivatives that showed potent inhibitory activities for both enzymes. Among them, 3-chloro-4-{[1-(4-phenoxybenzyl)in

A Cycloaddition Approach toward the Synthesis of Substituted Indolines and Tetrahydroquinolines

The intramolecular Diels-Alder reaction of 2-substituted aminofurans (IMDAF) results in the formation of various indolines and tetrahydroquinolines. The isolation of these ring systems from the IMDAF reaction can be rationalized in terms of an initial [4 + 2]-cycloaddition that first produces an oxa-bridged cycloadduct, which was not detected since it readily underwent nitrogen-assisted ring opening. Proton exchange followed by an eventual dehydration provides the aromatic product. In certain cases, the intermediate cyclohexadienol can be isolated and independently converted to the final product in high yield. The starting 2-aminofurans were readily prepared from furanyl acyl azide by a Curtius rearrangement in the presence of an alcohol. Alkylation of the resulting N-alkyl carbamate with an alkenyl bromide allows for the synthesis of a wide variety of cycloaddition precursors. The scope of the IMDAF reaction was evaluated by using mono- and disubstituted alkenes, electron rich and electron deficient olefins, and acetylenic tethers. Cyclic 2-amidofurans were also synthesized using a related intramolecular Diels-Alder reaction of 2-amido-substituted oxazoles which contain a tethered alkyne. This transformation represents a new route to this rare heterocyclic ring system. The sequential cycloaddition method was used for a formal synthesis of the pyrrolophenanthridone alkaloid hippadine.